OBJECTIVE: To determine the predictors for early versus later (breastfeeding) transmission of HIV-1. METHODS: Secondary data analysis was performed on HIV Network for Prevention Trials 012, a completed randomized clinical trial assessing the relative efficacy of nevirapine (NVP) versus zidovudine in reducing mother-to-child transmission (MTCT) of HIV-1. We used Cox regression analysis to assess risk factors for MTCT. The ViroSeq HIV genotyping and a sensitive point mutation assay were used to detect NVP resistance mutations. RESULTS: In this subset analyses, 122 of 610 infants were HIV infected, of whom 99 (81.1%) were infected early (first positive polymerase chain reaction < or =56 days). Incidence of MTCT after 56 days was low [0.7% per month (95% confidence interval, CI: 0.4 to 1.0)], but continued through 18 months. In multivariate analyses, early MTCT "factors" included NVP versus zidovudine (hazard ratio (HR) = 0.57, 95% CI: 0.38 to 0.86), pre-entry maternal viral load (VL, HR = 1.76, 95% CI: 1.28 to 2.41), and CD4 cell count (HR = 1.16, 95% CI: 1.05 to 1.28). Maternal VL (6-8 weeks) was associated with late MTCT (HR = 3.66, 95% CI: 1.78 to 7.50), whereas maternal NVP resistance (6-8 weeks) was not. CONCLUSIONS:Maternal VL was the best predictor of both early and late transmission. Maternal NVP resistance at 6-8 weeks did not predict late transmission.
RCT Entities:
OBJECTIVE: To determine the predictors for early versus later (breastfeeding) transmission of HIV-1. METHODS: Secondary data analysis was performed on HIV Network for Prevention Trials 012, a completed randomized clinical trial assessing the relative efficacy of nevirapine (NVP) versus zidovudine in reducing mother-to-child transmission (MTCT) of HIV-1. We used Cox regression analysis to assess risk factors for MTCT. The ViroSeq HIV genotyping and a sensitive point mutation assay were used to detect NVP resistance mutations. RESULTS: In this subset analyses, 122 of 610 infants were HIV infected, of whom 99 (81.1%) were infected early (first positive polymerase chain reaction < or =56 days). Incidence of MTCT after 56 days was low [0.7% per month (95% confidence interval, CI: 0.4 to 1.0)], but continued through 18 months. In multivariate analyses, early MTCT "factors" included NVP versus zidovudine (hazard ratio (HR) = 0.57, 95% CI: 0.38 to 0.86), pre-entry maternal viral load (VL, HR = 1.76, 95% CI: 1.28 to 2.41), and CD4 cell count (HR = 1.16, 95% CI: 1.05 to 1.28). Maternal VL (6-8 weeks) was associated with late MTCT (HR = 3.66, 95% CI: 1.78 to 7.50), whereas maternal NVP resistance (6-8 weeks) was not. CONCLUSIONS: Maternal VL was the best predictor of both early and late transmission. Maternal NVP resistance at 6-8 weeks did not predict late transmission.
Authors: R Nduati; G John; D Mbori-Ngacha; B Richardson; J Overbaugh; A Mwatha; J Ndinya-Achola; J Bwayo; F E Onyango; J Hughes; J Kreiss Journal: JAMA Date: 2000-03-01 Impact factor: 56.272
Authors: J E Embree; S Njenga; P Datta; N J Nagelkerke; J O Ndinya-Achola; Z Mohammed; S Ramdahin; J J Bwayo; F A Plummer Journal: AIDS Date: 2000-11-10 Impact factor: 4.177
Authors: S H Eshleman; G Becker-Pergola; M Deseyve; L A Guay; M Mracna; T Fleming; S Cunningham; P Musoke; F Mmiro; J B Jackson Journal: J Infect Dis Date: 2001-08-13 Impact factor: 5.226
Authors: Ibou Thior; Shahin Lockman; Laura M Smeaton; Roger L Shapiro; Carolyn Wester; S Jody Heymann; Peter B Gilbert; Lisa Stevens; Trevor Peter; Soyeon Kim; Erik van Widenfelt; Claire Moffat; Patrick Ndase; Peter Arimi; Poloko Kebaabetswe; Patson Mazonde; Joseph Makhema; Kenneth McIntosh; Vladimir Novitsky; Tun-Hou Lee; Richard Marlink; Stephen Lagakos; Max Essex Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: G C John; R W Nduati; D A Mbori-Ngacha; B A Richardson; D Panteleeff; A Mwatha; J Overbaugh; J Bwayo; J O Ndinya-Achola; J K Kreiss Journal: J Infect Dis Date: 2000-12-15 Impact factor: 5.226
Authors: S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson Journal: AIDS Date: 2001-10-19 Impact factor: 4.177
Authors: Carla J Chibwesha; Mark J Giganti; Nande Putta; Namwinga Chintu; Jessica Mulindwa; Benjamin J Dorton; Benjamin H Chi; Jeffrey S A Stringer; Elizabeth M Stringer Journal: J Acquir Immune Defic Syndr Date: 2011-10-01 Impact factor: 3.731
Authors: Taha E Taha; Maria M James; Donald R Hoover; Jin Sun; Oliver Laeyendecker; Caroline E Mullis; Johnstone J Kumwenda; Jairam R Lingappa; Bertran Auvert; Charles S Morrison; Lynne M Mofensen; Allan Taylor; Mary G Fowler; Newton I Kumenda; Susan H Eshleman Journal: AIDS Date: 2011-07-17 Impact factor: 4.177
Authors: Nicole L Davis; William C Miller; Michael G Hudgens; Charles S Chasela; Dorothy Sichali; Dumbani Kayira; Julie A E Nelson; Susan A Fiscus; Gerald Tegha; Deborah D Kamwendo; Joseph Rigdon; Jeffrey S A Stringer; Jonathan J Juliano; Sascha R Ellington; Athena P Kourtis; Denise J Jamieson; Charles van der Horst Journal: J Acquir Immune Defic Syndr Date: 2016-12-15 Impact factor: 3.731
Authors: A E Ezeamama; C Duggan; K P Manji; D Spiegelman; E Hertzmark; R J Bosch; R Kupka; J O Okuma; R Kisenge; S Aboud; W W Fawzi Journal: HIV Med Date: 2013-11-11 Impact factor: 3.180
Authors: Vladimir Novitsky; Rui Wang; Hermann Bussmann; Shahin Lockman; Marianna Baum; Roger Shapiro; Ibou Thior; Carolyn Wester; C William Wester; Anthony Ogwu; Aida Asmelash; Rosemary Musonda; Adriana Campa; Sikhulile Moyo; Erik van Widenfelt; Madisa Mine; Claire Moffat; Mompati Mmalane; Joseph Makhema; Richard Marlink; Peter Gilbert; George R Seage; Victor DeGruttola; M Essex Journal: PLoS One Date: 2010-04-12 Impact factor: 3.240
Authors: Anthony Ogwu; Sikhulile Moyo; Kathleen Powis; Aida Asmelash; Shahin Lockman; Claire Moffat; Jean Leidner; Joseph Makhema; Max Essex; Roger Shapiro Journal: Trop Med Int Health Date: 2016-06-16 Impact factor: 2.622